Chest wall oscillation

Insights on the Airway Clearance System North American Market to 2025 - Industry Analysis and Forecast

Retrieved on: 
Tuesday, December 1, 2020
Chest wall oscillation, Oscillation, Respiratory therapy, Airway clearance therapy

DUBLIN, Dec. 1, 2020 /PRNewswire/ -- The "North America Airway Clearance System Market, by Type,, by Application, by End Use, by Country, Industry Analysis and Forecast, 2019 - 2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Dec. 1, 2020 /PRNewswire/ -- The "North America Airway Clearance System Market, by Type,, by Application, by End Use, by Country, Industry Analysis and Forecast, 2019 - 2025" report has been added to ResearchAndMarkets.com's offering.
  • High-frequency chest wall oscillation (HFCWO) is an airway clearing technique that uses a modified vest to administer external chest wall oscillations to the torso.
  • Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
  • The market research report covers the analysis of key stake holders of the market.

Europe Airway Clearance System Market to 2025 - by Type, Application, End-use, and Country - ResearchAndMarkets.com

Retrieved on: 
Monday, November 9, 2020
Medical devices, Health, Respiratory diseases, Clinical medicine, Pulmonology, Chronic lower respiratory diseases, Respiratory therapy, Bronchitis, Respiratory disease, Cystic fibrosis, Lung, COPD: Journal of Chronic Obstructive Pulmonary Disease, Chronic obstructive pulmonary disease, Chest wall oscillation

The "Europe Airway Clearance System Market, by Type, by Application, by End Use, by Country, Industry Analysis and Forecast, 2019 - 2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Europe Airway Clearance System Market, by Type, by Application, by End Use, by Country, Industry Analysis and Forecast, 2019 - 2025" report has been added to ResearchAndMarkets.com's offering.
  • The airway clearance systems market is very competitive and has the involvement of Tier 1 and Tier 2 companies as well as many small businesses.
  • The growing adoption of airway clearance systems for the treatment of chronic obstructive pulmonary disease (COPD), cystic fibrosis, and chronic bronchitis drives market growth.
  • Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

Airway Clearance Systems Market Size Worth $698.11 Million by 2026: Grand View Research, Inc.

Retrieved on: 
Wednesday, November 13, 2019
RTT, Medical specialties, Organ systems, Medicine, Channelopathies, Cystic fibrosis, Aptalis, Bronchiectasis, Respiratory therapy, Chest wall oscillation

SAN FRANCISCO, Nov. 13, 2019 /PRNewswire/ -- The global airway clearance systems market size is expected to reach USD 698.11 million by 2026, registering a CAGR of 4.5%over the forecast period, according to a new report by Grand View Research, Inc.

Key Points: 
  • SAN FRANCISCO, Nov. 13, 2019 /PRNewswire/ -- The global airway clearance systems market size is expected to reach USD 698.11 million by 2026, registering a CAGR of 4.5%over the forecast period, according to a new report by Grand View Research, Inc.
  • Rising adoption of clearance system to curb the surmounting prevalence of cystic fibrosis, Chronic Obstructive Pulmonary Disease (COPD), bronchiectasis is the primary market driver.
  • Key players operating in the airway clearance systems market are Hill-Rom Holdings, Inc.; Electromed Inc.; Aptalis Pharma U.S. Inc.; and Thayer Medical.
  • Grand View Research has segmented the global airway clearance systems market based on device type, application, end use, and region:
    Airway Clearance Systems Device Type Outlook (Revenue, USD Million, 2014 - 2026)
    Airway Clearance Systems Application Outlook (Revenue, USD Million, 2014 - 2026)

Airway Clearance Systems Market Size Worth $698.11 Million by 2026: Grand View Research, Inc.

Retrieved on: 
Wednesday, November 13, 2019
RTT, Medical specialties, Organ systems, Medicine, Channelopathies, Cystic fibrosis, Aptalis, Bronchiectasis, Respiratory therapy, Chest wall oscillation

SAN FRANCISCO, Nov. 13, 2019 /PRNewswire/ -- The global airway clearance systems market size is expected to reach USD 698.11 million by 2026, registering a CAGR of 4.5%over the forecast period, according to a new report by Grand View Research, Inc.

Key Points: 
  • SAN FRANCISCO, Nov. 13, 2019 /PRNewswire/ -- The global airway clearance systems market size is expected to reach USD 698.11 million by 2026, registering a CAGR of 4.5%over the forecast period, according to a new report by Grand View Research, Inc.
  • Rising adoption of clearance system to curb the surmounting prevalence of cystic fibrosis, Chronic Obstructive Pulmonary Disease (COPD), bronchiectasis is the primary market driver.
  • Key players operating in the airway clearance systems market are Hill-Rom Holdings, Inc.; Electromed Inc.; Aptalis Pharma U.S. Inc.; and Thayer Medical.
  • Grand View Research has segmented the global airway clearance systems market based on device type, application, end use, and region:
    Airway Clearance Systems Device Type Outlook (Revenue, USD Million, 2014 - 2026)
    Airway Clearance Systems Application Outlook (Revenue, USD Million, 2014 - 2026)

First-Of-Its-Kind Independent Study Finds SmartVest® Reduces Exacerbations, Antibiotic Use, and Stabilizes Lung Function as Part of a Treatment Algorithm

Retrieved on: 
Thursday, June 27, 2019
Biotechnology, Managed care, Health, Medical devices, Hospitals, Other Health, Medicine, RTT, Clinical medicine, Pulmonology, Bronchiectasis, Chest wall oscillation, Lung, Respiratory therapy, Respiratory diseases, Allergic bronchopulmonary aspergillosis, Rare diseases

The study also demonstrated stability of lung function post algorithm-based treatment, suggesting early initiation of high frequency chest wall oscillation (HFCWO) therapy may slow the otherwise normal progression of the disease.

Key Points: 
  • The study also demonstrated stability of lung function post algorithm-based treatment, suggesting early initiation of high frequency chest wall oscillation (HFCWO) therapy may slow the otherwise normal progression of the disease.
  • Bronchiectasis is an irreversible, chronic lung condition characterized by enlarged and permanently damaged bronchi.
  • The study was an observational comparative retrospective cohort study evaluating the efficacy of a treatment algorithm in 65 patients with radiographic and symptom confirmed bronchiectasis.
  • The results speak for themselves: early initiation of therapy decreases severe exacerbations, reduces antibiotic use, and stabilizes lung function for bronchiectasis patients.